Pazopanib: An antiangiogenic drug in perspective

Carlos A. Castaneda; Henry L. Gomez

doi:10.2217/fon.09.112

Pazopanib: An antiangiogenic drug in perspective

Carlos A. Castaneda
, Henry L. Gomez

Instituto Nacional de Enfermedades Neoplásicas Eduardo Cáceres Graziani

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

Original language	English
Pages (from-to)	1335-1348
Number of pages	14
Journal	Future Oncology
Volume	5
Issue number	9
DOIs	https://doi.org/10.2217/fon.09.112
State	Published - 2009
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Angiogenesis
Breast
Cervix
Glyomas
Lung
Multiple myeloma
Ovarian
Pazopanib
Renal
Sarcomas
Thyroid
Tyrosine kinase
VEGF

Access to Document

10.2217/fon.09.112

Cite this

@article{bdc52d7e0bfd42e595af9b5749dbe0f6,

title = "Pazopanib: An antiangiogenic drug in perspective",

abstract = "Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.",

keywords = "Angiogenesis, Breast, Cervix, Glyomas, Lung, Multiple myeloma, Ovarian, Pazopanib, Renal, Sarcomas, Thyroid, Tyrosine kinase, VEGF",

author = "Castaneda, \{Carlos A.\} and Gomez, \{Henry L.\}",

year = "2009",

doi = "10.2217/fon.09.112",

language = "Ingl{\'e}s",

volume = "5",

pages = "1335--1348",

journal = "Future Oncology",

issn = "1479-6694",

number = "9",

}

TY - JOUR

T1 - Pazopanib

T2 - An antiangiogenic drug in perspective

AU - Castaneda, Carlos A.

AU - Gomez, Henry L.

PY - 2009

Y1 - 2009

N2 - Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

AB - Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

KW - Angiogenesis

KW - Breast

KW - Cervix

KW - Glyomas

KW - Lung

KW - Multiple myeloma

KW - Ovarian

KW - Pazopanib

KW - Renal

KW - Sarcomas

KW - Thyroid

KW - Tyrosine kinase

KW - VEGF

UR - https://www.scopus.com/pages/publications/74949120519

U2 - 10.2217/fon.09.112

DO - 10.2217/fon.09.112

M3 - Artículo de revisión

C2 - 19903063

AN - SCOPUS:74949120519

SN - 1479-6694

VL - 5

SP - 1335

EP - 1348

JO - Future Oncology

JF - Future Oncology

IS - 9

ER -

Pazopanib: An antiangiogenic drug in perspective

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this